Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China

被引：0
|
作者：
Huahua Zhang
Yandong Zhang
Chaonan Huang
Jiangfeng Wang
机构：
[1] Fuyang Hospital of Traditional Chinese Medicine,Department of Pharmacy
[2] Fuyang Hospital of Traditional Chinese Medicine,Department of Gynaecology
[3] Ipharmacare Ltd.,Department of Pharmaceutical Services
来源：
Clinical Drug Investigation | 2021年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：569 / 577
页数：8
相关论文
共 50 条
  • [21] Trastuzumab (Herceptin®) for treatment of HER2-positive metastatic breast cancer:: a cost-effectiveness analysis.
    Hornberger, J
    Foutel, V
    Kerrigan, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S136 - S136
  • [22] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
  • [23] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122
  • [24] The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence
    Giuliani, Jacopo
    Bonetti, Andrea
    BREAST JOURNAL, 2021, 27 (01): : 75 - 76
  • [25] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [26] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [27] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
  • [28] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [29] Cost-effectiveness of adjuvant chemotherapy plus trastuzumab (T) in HER2-positive breast cancer
    Liberato, N. L.
    Marchetti, M.
    Barosi, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI6 - XI6
  • [30] The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
    Li, Lu
    Yang, Shilei
    Fang, Fengqi
    Tian, Li
    He, Ying
    Li, Jia
    Chen, Yanwei
    Dong, Deshi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345